BioDelivery Sciences International Receives Initial $2 Million Payment For Development Of BEMA(TM) Fentanyl; First Installment Of Up To $7 Million

MORRISVILLE, N.C.--(BUSINESS WIRE)--Feb. 16, 2006--BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty biopharmaceutical company, has received an initial $2 million payment under a previously announced clinical development and license agreement with CDC IV LLC, an affiliate of Clinical Development Capital, LLC (“CDC”). This resulted from BDSI achieving certain key milestones in the clinical development of its BEMA(TM) Fentanyl formulation.